// App-Quantinova.ai

AB0282 (2022) : COMORBIDITIES ARE MORE IMPORTANT THAN JAK INHIBITORS: VENOUS THROMBOEMBOLISM IN RHEUMATOID ARTHRITIS

Researchers

Presenter

  • G. Sandal Uzun

Principal Investigators

  • M. Bahap

  • O. Yucel

  • Y. Kaygusuz

  • E. Bilgin

  • L. Kili

  • A. Akdogan

  • O. Karadag

  • S. A. Bilgen

  • S. Kiraz

  • A. I. Ertenli

  • U. Kalyoncu

Medical Centers

  • Ankara, Hacettepe University, Faculty of Medicine; Division of Rheumatology, Department of Internal Medicine; Hacettepe University Medical Faculty Department of Internal Medicine Division of Rheumatology, Çankaya, Turkey

  • Hacettepe University School of Pharmacy, Department of Clinical Pharmacy, Ankara, Turkey

Locations

  • Turkey

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Venous thrombosis

  • Rheumatoid arthritis

  • Inflammatory Arthritis

Biomarkers

  • Janus kinase

  • Albumin/creatinine

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved